Hemophilia A research study for pregnant families
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Women’s health & pregnancy clinical trials.
This study follows pregnant people who carry a severe hemophilia A gene and their babies after birth. It looks at how hemophilia A is passed down and how it affects families, with the goal of improving understanding and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and pregnant (before 37 weeks of pregnancy)
- You have or might have a severe hemophilia A gene
- Your baby has a high chance of having severe hemophilia A
- You can understand and agree to the study
- Your baby will be born and get regular care in the United States
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This Phase 1/2 study tests a one-time gene therapy (ASC618) to help the body make clotting factor for people with hemophilia A. It may reduce bleeding and the need for factor infusions, but you must meet several safety and eligibility checks.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.